Close

Edwards Lifesciences (EW) Announces Strong SAPIEN 3 TAVR Data vs. Surgery

Go back to Edwards Lifesciences (EW) Announces Strong SAPIEN 3 TAVR Data vs. Surgery

Stifel Raises Price Target on Edwards Lifesciences (EW) to $117; Reiterates Buy

April 4, 2016 10:33 AM EDT

Stifel reiterated a Buy rating on Edwards Lifesciences (NYSE: EW), and raised the price target to $117.00 (from $98.00), following data presentations at American College of Cardiology. Given the outstanding data, Stifel is increasing its 2016-2020 revenue and EPS projections. On EPS, they now project 2016 at $2.67, up $0.06 from prior estimates and 2017 moves to $3.36, up $0.36 or 12% vs prior projection.

Analyst Rick Wise... More

Edwards Lifesciences (EW) Raising Estimates, PT on Better Than Expected Sapien 3 Data - Leerink Partners

April 4, 2016 7:50 AM EDT

Leerink Partners analyst, Danielle Antalffy, raised her PT on Edwards Lifesciences by nearly 25% to $115 to account for better than expected Sapien 3 intermediate risk data. No change to Outperform rating.

Sapien 3 is demonstrating significant superiority vs. surgery in intermediate risk patients which drives estimates higher while still leaving meaningful room for upside. Given the positive Sapien 3 data in intermediate risk patients -- which demonstrated superiority vs.... More

BTIG Upgrades Edwards Lifesciences (EW) to Buy

April 4, 2016 7:35 AM EDT

BTIG upgraded Edwards Lifesciences (NYSE: EW) from Neutral to Buy with a price target of $115. The upgrade follows strong SAPIEN 3... More

Edwards Lifesciences (EW) PT Raised to $98 at Credit Suisse Following Sapien Data

April 4, 2016 7:21 AM EDT

Credit Suisse analyst M. Keeler raised its price target on Outperform-rated Edwards Lifesciences (NYSE: EW) to $98.00 (from $88.00) after 1 year Sapien 3 TAVI data in intermediate risk patients showed TAVI to be superior vs. surgery on a primary endpoint of mortality, stroke or moderate to severe... More

Edwards Lifesciences (EW) PT Raised to at Jefferies Following PARTNER II Sapien 3 Data

April 4, 2016 6:45 AM EDT

Jefferies analyst Raj Denhoy reiterated a Buy rating and boosted his price target on Edwards Lifesciences (NYSE: EW) to $105.00 (from $100.00) after the much anticipated PARTNER II Sapien 3 data did not disappoint.

Denho commented, "Showing superiority to surgery on the primary endpoint... More

Edwards Lifesciences (EW) Catalyst: ACC Meeting

April 1, 2016 8:24 AM EDT

UBS's Edwards Lifesciences (NYSE: EW) analyst, Matt Miksic performed a historical event analysis of 10 late breaking clinical trials over the past 10 years and found that the positive impact of late-breaking clinical data is rarely reflected in stocks until after it hits the tape. Specifically, stocks... More